abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapelocationmap-pinminusnewsorganisationotheroverviewpluspreviewprofilerefreshnewssearchsecurityPathtagticktooltiptwitteruniversalityweb

このページは 日本語 では利用できません。{displayed language} で表示されています。English

ストーリー

Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

In January 2014, the Innovative Pharmaceutical Association of South Africa (IPASA) was accused of planning and funding an advocacy campaign on behalf of its member companies. The campaign allegedly sought to oppose South Africa’s efforts to introduce intellectual property law reforms that would allow for patents belonging to IPASA’s member companies to be limited, and for cheaper generic versions to be produced.

In a leaked email, Merck and other members of IPASA discussed the strategy.

Media items on the IPASA campaign:

 

Business & Human Rights Resource Centre invited IPASA and its member companies to respond:

Members companies' responses & non-responses:

  • Abbott [We have invited Abbott to respond and will indicate here whether it responds]
  • Abbvie [We have invited Abbvie to respond and will indicate here whether it responds]
  • Alcon (part of Novartis) Novartis responded [PDF] on behalf of itself and Alcon
  • Allergan did not respond
  • Amgen [We have invited Amgen to respond and will indicate here whether it responds]
  • AstraZeneca response [PDF]
  • Baxter response [PDF]
  • Bayer response [PDF]
  • Boehringer-Ingelheim response [PDF]
  • Bristol-Myers Squibb referred us to IPASA
  • Covidien [We have invited Covidien to respond and will indicate here whether it responds]
  • Eli Lilly [We have invited Eli Lilly to respond and will indicate here whether it responds]
  • Ferring [We have invited Ferring to respond and will indicate here whether it responds]
  • Galderma response [PDF]
  • GE Health reffered us to IPASA
  • Johnson & Johnson response [PDF]
  • Merck (MSD) response [PDF]
  • Novartis response [PDF]
  • Novo Nordisk response [PDF] indicates it resigned from IPASA following campaign proposal:
  • Norgine [We have invited Norgine to respond and will indicate here whether it responds]
  • Pfizer referred us to IPASA
  • Roche response [PDF] indicates it resigned from IPASA following campaign proposal
  • Sanofi-Aventis [We have invited Sanofi-Aventis to respond and will indicate here whether it responds]
  • Servier [We have invited Servier to respond and will indicate here whether it responds]
  • Takeda referred us to IPASA

 

Novo Nordisk and Roche resigned from IPASA:

企業への回答リクエスト

Abbott Laboratories

ノーレスポンス

AbbVie

ノーレスポンス

Allergan 回答を見る
Amgen

ノーレスポンス

AstraZeneca 回答を見る
Baxter International 回答を見る
Boehringer Ingelheim 回答を見る
Bristol-Myers Squibb 回答を見る
Covidien 回答を見る
Eli Lilly 回答を見る
Ferring Pharmaceuticals

ノーレスポンス

Galderma 回答を見る
GE Health (part of General Electric) 回答を見る
Johnson & Johnson 回答を見る
Norgine Pharmaceuticals 回答を見る
Novartis 回答を見る
Novo Nordisk (part of Novo Group) 回答を見る
Sanofi

ノーレスポンス

Servier

ノーレスポンス

Takeda Pharmaceutical 回答を見る

Story Timeline